-
Company Insights
Innovation and Patenting activity of Camurus AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Camurus AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Leuprolide Acetate in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leuprolide Acetate in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leuprolide Acetate in Metastatic Prostate Cancer Drug Details: Leuprolide acetate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Granisetron in Chemotherapy Induced Nausea and Vomiting
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Granisetron in Chemotherapy Induced Nausea and Vomiting report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Granisetron in Chemotherapy Induced Nausea and Vomiting Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cagrilintide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cagrilintide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cagrilintide in Obesity Drug Details: Cagrilintide is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Treprostinil SR in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil SR in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil SR in Pulmonary Arterial Hypertension Drug Details: Treprostinil(CAM-2043) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil SR in Raynauds Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil SR in Raynauds Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil SR in Raynauds Disease Drug Details: Treprostinil(CAM-2043) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Octreotide LA in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide LA in Neuroendocrine Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide LA in Neuroendocrine Tumors Drug Details: Octreotide long-acting (CAM-2029)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Octreotide LA in Acromegaly
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide LA in Acromegaly report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide LA in Acromegaly Drug Details: Octreotide long-acting (CAM-2029) is under...
-
Product Insights
Raynauds Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Raynauds Disease - Drugs In Development, 2023’, provides an overview of the Raynauds Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...